Merck + Co., Inc.

Merck Sharp + Dohme Corp.

David C Dubost

Michael J Kaufman

Jerome P Draper

John S Wai

John M Williams

Peter D Williams

Shankar Venkatraman

Wayne J Thompson

Richard John Varsolona

Dai-Shi Su

Mark W Embrey

Peter Emmanuel Maligres

Zhiguo Jake Song

James A McCauley

Majid Mahjour

Thorsten E Fisher

Daniel Richard Sidler

Tao Pei

David Hamilton Harris

Jingjun Yin

William A Hunke

Michael Shevlin

Richard C A Isaacs

Neil A Strotman

Mandana Asgharnejad

Richard G Ball

Matthew L Maddess

Dietrich P Steinhuebel

Jennifer L Vandrilla

Dan Zhang

Eric J Choi

David Storey

Jeffrey A Zimmerman

Paul A Bergquist

Lisa M DiMichele

Sarah L Trice

Neil Campbell

Lixia Cai

Yongjun Li

Matthew Maddess

Disclosed are pharmaceutical compositions comprising tedizolid phosphate, methods of preparing such pharmaceutical compositions, and methods of treating bacterial infections with such pharmaceutical compositions. Specifically, a pharmaceutical composition comprising tedizolid phosphate, an acid; and a suspending agent; and wherein the pH of the composition upon constitution with water is between about pH 2-4.5, is provided, wherein the acid is not citric acid or malic acid.

Pharmaceutical compositions of tedizolid phosphate

Compounds of Formula I are inhibitors of HIV integrase and inhibitors of HIV replication: wherein X, X, Y, R, R, Rand Rare defined herein. The compounds are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset or progression of AIDS. The compounds are employed against HIV infection and AIDS as compounds per se (or as hydrates or solvates thereof) or in the form of pharmaceutically acceptable salts. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Processes for making compounds of Formula I and intermediates thereof are also described.

HIV integrase inhibitors

Wet granulation formulation of a growth hormone secretagogue

A pharmaceutical composition is disclosed which contains a compound of formula I: ##STR1## or a pharmaceutically acceptable salt, prodrug or hydrate thereof, in the stabilized form and/or in combination with a carbon dioxide source.

Carbapenem antibiotic

This invention is concerned with polymorphic forms of the compound N-�1(R)-�(1,2-dihydro-1-methanesulfonylspiro�3H-indole-3,4'-piperdin!-1'-y l)carbonyl!-2-(phenylmethyloxy)ethyl!-2-amino-2-methylpropanamide methanesulfonate which is a growth hormone secretagogue that is useful in food animals to promote their growth thereby rendering the production of edible meat products more efficient, and in humans, to treat physiological or medical conditions characterized by a deficiency in growth hormone secretion, and to treat medical conditions which are improved by the anabolic effects of growth hormone. The instant polymorphic forms have advantages over the other known forms of N-�1(R)-�(1,2-dihydro-1-methanesulfonylspiro�3H-indole-3,4'-piperdin!-1'-y l)carbonyl!-2-(phenylmethyloxy)-ethyl!-2-amino-2-methylpropanamide methanesulfonate in terms of thermodynamic stability and suitability for inclusion in pharmaceutical formulations. The present invention is also concerned with processes for preparing these polymorphic forms, pharmaceutical formulations comprising these polymorphic forms as active ingredients and the use of the polymorphic form of the compound and their formulations in the treatment of certain disorders.

Polymorphic forms of a growth hormone secretagogue

Growing community of inventors

Collegeville, PA, United States of America

David C Dubost